Semaglutide news

All news on Semaglutide (also known as Wegovy and Ozempic): plants, production capacities, investments and involved companies in Europe.

18 September 2025
Novo Nordisk: Ozempic® Cuts Heart Attack, Stroke, and Death Risk by 23% vs. Dulaglutide
Ozempic® shows 26% lower death risk and 25% reduced risk of major cardiovascular events in older diabetes patients compared to dulaglutide in a real-world study.
17 September 2025
Novo Nordisk's Oral Semaglutide Achieves 16.6% Weight Loss in Obesity Study
Oral semaglutide 25 mg shows significant weight loss and improved physical activity in a 64-week trial, with mild to moderate side effects, pending FDA approval.
16 September 2025
Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results
Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.
15 September 2025
Novo Nordisk's Wegovy® Reduces Food Noise, Enhances Mental Well-being
Wegovy® users reported a 46% drop in constant food thoughts, improved mental health (64%), and healthier habits (80%) in a real-world survey.
15 September 2025
Novo Nordisk's Oral Semaglutide Approved in EU for Cardiovascular Benefits
EMA approves Rybelsus® label update for cardiovascular benefits in type 2 diabetes. SOUL trial shows reduced hospitalizations and consistent benefits across BMI and weight.
5 September 2025
Novo Nordisk to Present Semaglutide and Pipeline Data at EASD Congress
Novo Nordisk to present data on semaglutide's effects on food noise, body composition, and cardiovascular benefits, plus new obesity treatments at EASD 2025.

Who will be producing Semaglutide in the future?

Find out with chemXplore Analytics